FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation
You may also be interested in...
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms
Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity
Generic Drug Reforms: FTC Notification Bill Appears Ready To Move In 2003
A bill to require reporting of brand/generic patent settlements to the Federal Trade Commission appears ready to move early in the 108th Congress